Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Nicotine Pharmacokinetics and Pharmacodynamics, Safety and Tolerability of P3P

21 januari 2020 uppdaterad av: Philip Morris Products S.A.

A Single-center, Open-label, Randomized, Crossover Study to Investigate the Nicotine Pharmacokinetic Profile, Pharmacodynamics, Safety and Tolerability of Four P3P Variants in Smoking Healthy Adult Subjects

This is a single-center, open-label, randomized, crossover study to evaluate the pharmacokinetic (PK) profiles of four P3P variants (differing in nicotine aerosol particle size, nicotine concentration and in the absence or presence of a flavoring system), following a fixed puffing regimen and an ad libitum use period. In addition, pharmacodynamic (PD) effects (subjective effects and related behavioral assessments), as well as human puffing topography, will be evaluated, to provide further insights on product safety, acceptance, and use.

Studieöversikt

Status

Avslutad

Betingelser

Intervention / Behandling

Detaljerad beskrivning

The goal of the proposed study is to evaluate the pharmacokinetic profiles of four P3P variants. Variants with two different nicotine contents (1 mg/product and 2 mg/product), two different nicotine aersol particle sizes and presence/absence of a flavoring system will be tested to identify which one would yield plasma nicotine concentrations as close as possible to those achieved after smoking a single cigarette. All of the subjects will initially use the lowest nicotine content product (P3P 3). Subject will continue the study using the three remaining products (P3P 1, P3P 2 and P3P 4) containing 2 mg nicotine/product in a randomly assigned sequence.

Two product use regimens: fixed puffing and ad libitum use will be applied to provide insight into nicotine absorption. The fixed puffing regimen with consistent use conditions across subjects will be applied in order to minimize variability. The 1 hour ad libitum use period will provide information on nicotine PK and product acceptance when subjects use the P3P according to their own puffing behavior which is closer to a real-world setting.

Safety and tolerability will also be assessed throughout the study.

Studietyp

Interventionell

Inskrivning (Faktisk)

19

Fas

  • Inte tillämpbar

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

  • Schweiz
    • Ticino
      • Arzo, Ticino, Schweiz, 6864
        • CROSS Research

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

21 år till 65 år (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Ja

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion criteria:

  • Subject has signed the Informed Consent Form (ICF) and is able to understand the information provided in the ICF.
  • Subject is between 21 and 65 years old.
  • Subject is Caucasian.
  • Smoking, healthy subject as judged by the Investigator or designee based on available assessments from the screening period.
  • Subject has been smoking at least 10 commercially available cigarettes per day at least for the last 4 weeks prior to Screening Visit. Smoking status will be verified based on a urinary cotinine test (cotinine ≥ 200 ng/mL).
  • Subject has been smoking for at least the last 3 years prior to Screening Visit.
  • Subject does not plan to quit smoking in the next 2 months after the Screening Visit.

Exclusion criteria:

  • Female subject is pregnant or breastfeeding.
  • Female subject uses estrogen-containing hormonal contraception or hormone replacement therapy.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Övrig
  • Tilldelning: Randomiserad
  • Interventionsmodell: Crossover tilldelning
  • Maskning: Ingen (Open Label)

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Aktiv komparator: Product Sequence 1

Subjects will be exposed to P3P 3 on day 1 of the study, then randomized to follow a sequence of product exposure comprised of:

P3P 2 on Day 2; P3P 4 on Day 3; P3P 1 on Day 4
Övrig: P3P 1
2 mg of nicotine; no flavor; nicotine powder particle size of 2.25 ± 0.2 μm
Övrig: P3P 2
2 mg of nicotine; flavor; nicotine powder particle size of 2.25 ± 0.2 μm
Övrig: P3P 3
1 mg of nicotine; flavor; nicotine powder particle size of 2.25 ± 0.2 μm
Övrig: P3P 4
2 mg of nicotine; flavor; nicotine powder particle size of 1.8 ± 0.2 μm
Aktiv komparator: Product Sequence 2

Subjects will be exposed to P3P 3 on day 1 of the study, then randomized to follow a sequence of product exposure comprised of:

P3P 4 on Day 2; P3P 1 on Day 3; P3P 2 on Day 4
Övrig: P3P 1
2 mg of nicotine; no flavor; nicotine powder particle size of 2.25 ± 0.2 μm
Övrig: P3P 2
2 mg of nicotine; flavor; nicotine powder particle size of 2.25 ± 0.2 μm
Övrig: P3P 3
1 mg of nicotine; flavor; nicotine powder particle size of 2.25 ± 0.2 μm
Övrig: P3P 4
2 mg of nicotine; flavor; nicotine powder particle size of 1.8 ± 0.2 μm
Aktiv komparator: Product Sequence 3

Subjects will be exposed to P3P 3 on day 1 of the study, then randomized to follow a sequence of product exposure comprised of:

P3P 1 on Day 2; P3P 2 on Day 3; P3P 4 on Day 4
Övrig: P3P 1
2 mg of nicotine; no flavor; nicotine powder particle size of 2.25 ± 0.2 μm
Övrig: P3P 2
2 mg of nicotine; flavor; nicotine powder particle size of 2.25 ± 0.2 μm
Övrig: P3P 3
1 mg of nicotine; flavor; nicotine powder particle size of 2.25 ± 0.2 μm
Övrig: P3P 4
2 mg of nicotine; flavor; nicotine powder particle size of 1.8 ± 0.2 μm
Aktiv komparator: Product Sequence 4

Subjects will be exposed to P3P 3 on day 1 of the study, then randomized to follow a sequence of product exposure comprised of:

P3P 1 on Day 2; P3P 4 on Day 3; P3P 2 on Day 4
Övrig: P3P 1
2 mg of nicotine; no flavor; nicotine powder particle size of 2.25 ± 0.2 μm
Övrig: P3P 2
2 mg of nicotine; flavor; nicotine powder particle size of 2.25 ± 0.2 μm
Övrig: P3P 3
1 mg of nicotine; flavor; nicotine powder particle size of 2.25 ± 0.2 μm
Övrig: P3P 4
2 mg of nicotine; flavor; nicotine powder particle size of 1.8 ± 0.2 μm
Aktiv komparator: Product Sequence 5

Subjects will be exposed to P3P 3 on day 1 of the study, then randomized to follow a sequence of product exposure comprised of:

P3P 2 on Day 2; P3P 1 on Day 3; P3P 4 on Day 4
Övrig: P3P 1
2 mg of nicotine; no flavor; nicotine powder particle size of 2.25 ± 0.2 μm
Övrig: P3P 2
2 mg of nicotine; flavor; nicotine powder particle size of 2.25 ± 0.2 μm
Övrig: P3P 3
1 mg of nicotine; flavor; nicotine powder particle size of 2.25 ± 0.2 μm
Övrig: P3P 4
2 mg of nicotine; flavor; nicotine powder particle size of 1.8 ± 0.2 μm
Aktiv komparator: Product Sequence 6

Subjects will be exposed to P3P 3 on day 1 of the study, then randomized to follow a sequence of product exposure comprised of:

P3P 4 on Day 2; P3P 2 on Day 3; P3P 1 on Day 4
Övrig: P3P 1
2 mg of nicotine; no flavor; nicotine powder particle size of 2.25 ± 0.2 μm
Övrig: P3P 2
2 mg of nicotine; flavor; nicotine powder particle size of 2.25 ± 0.2 μm
Övrig: P3P 3
1 mg of nicotine; flavor; nicotine powder particle size of 2.25 ± 0.2 μm
Övrig: P3P 4
2 mg of nicotine; flavor; nicotine powder particle size of 1.8 ± 0.2 μm

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Plasma Nicotine Concentration-time Profile
Tidsram: Derived from multiple blood sampling (measured at 2 mins, 4 mins, 7 mins, 10 mins, 15 mins, 30 mins, 1 hour, 2 hours, and 4 hours post-product use) on Days 1, 2, 3 and 4
To measure the plasma nicotine concentration-time profile of four P3P variants from the fixed puffing regimen, following correction of baseline nicotine levels.
Derived from multiple blood sampling (measured at 2 mins, 4 mins, 7 mins, 10 mins, 15 mins, 30 mins, 1 hour, 2 hours, and 4 hours post-product use) on Days 1, 2, 3 and 4
Maximum Plasma Concentration [Cmax]
Tidsram: Derived from multiple blood sampling (measured at 2 mins, 4 mins, 7 mins, 10 mins, 15 mins, 30 mins, 1 hour, 2 hours, and 4 hours post-product use) on Days 1, 2, 3 and 4
To measure the maximum nicotine plasma concentration [Cmax] of four P3P variants from the fixed puffing regimen, following correction of baseline nicotine levels.
Derived from multiple blood sampling (measured at 2 mins, 4 mins, 7 mins, 10 mins, 15 mins, 30 mins, 1 hour, 2 hours, and 4 hours post-product use) on Days 1, 2, 3 and 4
Time to the Maximum Nicotine Concentration [Tmax]
Tidsram: Derived from multiple blood sampling (measured at 2 mins, 4 mins, 7 mins, 10 mins, 15 mins, 30 mins, 1 hour, 2 hours, and 4 hours post-product use) on Days 1, 2, 3 and 4
To measure the time to maximum nicotine concentration [Tmax] of four P3P variants from the fixed puffing regimen, following correction of baseline nicotine levels.
Derived from multiple blood sampling (measured at 2 mins, 4 mins, 7 mins, 10 mins, 15 mins, 30 mins, 1 hour, 2 hours, and 4 hours post-product use) on Days 1, 2, 3 and 4
Area Under the Concentration-time Curve From Start of Product Use (T0 Fix) to 4 Hours [AUCfix (0-4h)]
Tidsram: Derived from multiple blood sampling (measured at 2 mins, 4 mins, 7 mins, 10 mins, 15 mins, 30 mins, 1 hour, 2 hours, and 4 hours post-product use) on Days 1, 2, 3 and 4
To measure the area under the plasma concentration-time curve of four P3P variants from the fixed puffing regimen, following correction of baseline nicotine levels.
Derived from multiple blood sampling (measured at 2 mins, 4 mins, 7 mins, 10 mins, 15 mins, 30 mins, 1 hour, 2 hours, and 4 hours post-product use) on Days 1, 2, 3 and 4

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Plasma Nicotine Concentration-time Profile
Tidsram: Derived from multiple blood sampling (measured at 10 mins, 20 mins, 30 mins, 40 mins, 1 hour, 2 hours, and 4 hours during and post-ad libitum use) on Days 1, 2, 3 and 4
To measure the plasma nicotine concentration-time profile of four P3P variants from the ad libitum use period, following correction of baseline nicotine levels.
Derived from multiple blood sampling (measured at 10 mins, 20 mins, 30 mins, 40 mins, 1 hour, 2 hours, and 4 hours during and post-ad libitum use) on Days 1, 2, 3 and 4
Peak Plasma Nicotine Concentration [Cpeak]
Tidsram: Derived from multiple blood sampling (measured at 10 mins, 20 mins, 30 mins, 40 mins, 1 hour, 2 hours, and 4 hours during and post-ad libitum use) on Days 1, 2, 3 and 4
To measure the Peak plasma nicotine concentration [Cpeak] of four P3P variants from the ad libitum use period, following correction of baseline nicotine levels.
Derived from multiple blood sampling (measured at 10 mins, 20 mins, 30 mins, 40 mins, 1 hour, 2 hours, and 4 hours during and post-ad libitum use) on Days 1, 2, 3 and 4
Time to Peak Plasma Nicotine Concentration [Tpeak]
Tidsram: Derived from multiple blood sampling (measured at 10 mins, 20 mins, 30 mins, 40 mins, 1 hour, 2 hours, and 4 hours during and post-ad libitum use) on Days 1, 2, 3 and 4
To measure the time to peak plasma nicotine concentration [Tpeak] of four P3P variants from the ad libitum use period, following correction of baseline nicotine levels.
Derived from multiple blood sampling (measured at 10 mins, 20 mins, 30 mins, 40 mins, 1 hour, 2 hours, and 4 hours during and post-ad libitum use) on Days 1, 2, 3 and 4
Trough Plasma Nicotine Concentration [Ctrough]
Tidsram: Derived from multiple blood sampling (measured at 10 mins, 20 mins, 30 mins, 40 mins, 1 hour, 2 hours, and 4 hours during and post-ad libitum use) on Days 1, 2, 3 and 4
To measure the trough plasma nicotine concentration [Ctrough] of four P3P variants from the ad libitum use period, following correction of baseline nicotine levels.
Derived from multiple blood sampling (measured at 10 mins, 20 mins, 30 mins, 40 mins, 1 hour, 2 hours, and 4 hours during and post-ad libitum use) on Days 1, 2, 3 and 4
Average of Plasma Nicotine Concentration From T0 ad Lib to 1 Hour [Caverage]
Tidsram: Derived from multiple blood sampling (measured at 10 mins, 20 mins, 30 mins, 40 mins, 1 hour during ad libitum use) on Days 1, 2, 3 and 4
To measure the average of plasma nicotine concentration [Caverage], of four P3P variants from the ad libitum use period, following correction of baseline nicotine levels
Derived from multiple blood sampling (measured at 10 mins, 20 mins, 30 mins, 40 mins, 1 hour during ad libitum use) on Days 1, 2, 3 and 4
Area Under the Concentration-time Curve From Start of Product Use (T0 ad Lib) to 4 Hours [AUCad Lib (0-4h)]
Tidsram: Derived from multiple blood sampling (measured at 10 mins, 20 mins, 30 mins, 40 mins, 1 hour, 2 hours, and 4 hours during and post-ad libitum use) on Days 1, 2, 3 and 4
To measure the area under the plasma concentration-time curve of four P3P variants from the ad libitum use period, following correction of baseline nicotine levels.
Derived from multiple blood sampling (measured at 10 mins, 20 mins, 30 mins, 40 mins, 1 hour, 2 hours, and 4 hours during and post-ad libitum use) on Days 1, 2, 3 and 4
AUC of Craving for a Cigarette During and After the Fixed Puffing Regimen
Tidsram: During and up to 4 hours post-product use on days 1, 2, 3 and 4
Measured on a Visual Analogue Scale (VAS) of 0 (no craving) to 100 (strong craving).
During and up to 4 hours post-product use on days 1, 2, 3 and 4
AUC Craving for a Cigarette During and After the ad Libitum Use Period
Tidsram: During and up to 4 hours post-product use on days 1, 2, 3 and 4
Measured on a Visual Analogue Scale (VAS) of 0 (no craving) to 100 (strong craving).
During and up to 4 hours post-product use on days 1, 2, 3 and 4
Product Evaluation
Tidsram: Within 60 minutes after the ad libitum use session on days 1, 2, 3 and 4
Measured with an adapted version of the modified Cigarette Evaluation Questionnaire (adapted mCEQ) following the ad libitum use period. Assessed on a 7-point scale, ranging from 1 (not at all) to 7 (extremely).
Within 60 minutes after the ad libitum use session on days 1, 2, 3 and 4
Sensory Parameters
Tidsram: Within 60 minutes after the ad libitum use session on days 1, 2, 3 and 4
Measured with a Sensory Questionnaire (SQ) following the ad libitum use period. Response to each question is assessed on a 7-point scale, ranging from 1 (not at all) to 7 (extremely).
Within 60 minutes after the ad libitum use session on days 1, 2, 3 and 4
Human Puffing Topography (HPT) Parameters (Puff Volume) of Four P3P Variants During the Fixed Puffing Regimen Period.
Tidsram: During fixed puffing product use on days 1, 2, 3 and 4
Descriptive statistics of total puff volume and average puff volume, of four P3P variants, during the fixed puffing regimen period.
During fixed puffing product use on days 1, 2, 3 and 4
Human Puffing Topography (HPT) Parameters (Puff Volume) of Four P3P Variants During the ad Libitum Use Period.
Tidsram: During ad libitum product use on days 1, 2, 3 and 4
Descriptive statistics of total puff volume and average puff volume, of four P3P variants, during the ad libitum use period.
During ad libitum product use on days 1, 2, 3 and 4
Amount of Powder Aerosolized From P3P From the Fixed Puffing Regimen.
Tidsram: Before and after fixed puffing product use on days 1, 2, 3 and 4
Descriptive statistics of P3P weight before use, and after use, for the fixed puffing regimen.
Before and after fixed puffing product use on days 1, 2, 3 and 4
Amount of Powder Aerosolized From P3P From the ad Libitum Use Period (Per Product Used).
Tidsram: Before and after ad libitum product use on days 1, 2, 3 and 4
P3P weight before use, and after use, to determine the amount of powder aerosolized from P3P during Ad Libitum use (per product used).
Before and after ad libitum product use on days 1, 2, 3 and 4

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Sponsor

Philip Morris Products S.A.

Utredare

  • Huvudutredare: Milko Radicioni, MD, CROSS Research, Arzo, Ticino, Switzerland

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

7 november 2017

Primärt slutförande (Faktisk)

1 februari 2018

Avslutad studie (Faktisk)

2 maj 2018

Studieregistreringsdatum

Först inskickad

22 november 2017

Först inskickad som uppfyllde QC-kriterierna

5 december 2017

Första postat (Faktisk)

12 december 2017

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

31 januari 2020

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

21 januari 2020

Senast verifierad

1 januari 2020

Mer information

Termer relaterade till denna studie

Nyckelord

Andra studie-ID-nummer

  • P3P-PK-01-CH

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

NEJ

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Kliniska prövningar på P3P 1

Sök liknande försök

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

CROs by country

CROs in Spain

Betingelser

Sällsynta sjukdomar

Läkemedelsinterventioner

Kosttillskott

Sponsor / medarbetare

Platser

3
Prenumerera